Thrivent Financial for Lutherans
MRNA icon

Thrivent Financial for Lutherans’s Moderna MRNA Stock Holding History

Thrivent Financial for Lutherans’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54M Sell
21,940
-8,537
-28% -$442K ﹤0.01% 1725
2026
Q1 		$1.55M Buy
30,477
+17,288
+131% +$807K ﹤0.01% 1615
2025
Q4 		$389K Sell
13,189
-152
-1% -$4.13K ﹤0.01% 2339
2025
Q3 		$345K Sell
13,341
-79,658
-86% -$2.22M ﹤0.01% 2195
2025
Q2 		$2.57M Buy
92,999
+79,726
+601% +$2.1M 0.01% 1188
2025
Q1 		$376K Sell
13,273
-12,261
-48% -$435K ﹤0.01% 2167
2024
Q4 		$1.06M Buy
25,534
+3
+0% +$143 ﹤0.01% 1861
2024
Q3 		$1.71M Sell
25,531
-180
-0.7% -$16.5K ﹤0.01% 1554
2024
Q2 		$3.05M Sell
25,711
-73
-0.3% -$9.24K 0.01% 1119
2024
Q1 		$2.75M Buy
25,784
+11,992
+87% +$1.21M 0.01% 1189
2023
Q4 		$1.37M Sell
13,792
-126
-0.9% -$10.6K ﹤0.01% 1641
2023
Q3 		$1.44M Sell
13,918
-15,011
-52% -$1.67M ﹤0.01% 1526
2023
Q2 		$3.52M Sell
28,929
-1,042
-3% -$139K 0.01% 1003
2023
Q1 		$4.59M Buy
29,971
+12,359
+70% +$2.04M 0.01% 845
2022
Q4 		$3.16M Buy
17,612
+1,471
+9% +$241K 0.01% 984
2022
Q3 		$1.91M Sell
16,141
-314
-2% -$47.6K 0.01% 1248
2022
Q2 		$2.35M Buy
16,455
+178
+1% +$25.4K 0.01% 1140
2022
Q1 		$2.8M Sell
16,277
-9,248
-36% -$1.56M 0.01% 1132
2021
Q4 		$6.43M Sell
25,525
-19,483
-43% -$5.7M 0.01% 815
2021
Q3 		$17.3M Sell
45,008
-9,270
-17% -$3.42M 0.04% 508
2021
Q2 		$12.8M Buy
54,278
+1,516
+3% +$271K 0.03% 612
2021
Q1 		$6.91M Buy
52,762
+47,347
+874% +$6.86M 0.02% 789
2020
Q4 		$566K Buy
+5,415
New +$548K ﹤0.01% 2078

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Thrivent Financial for Lutherans's MRNA Position: Q2 2026 in Review

Thrivent Financial for Lutherans reduced its Moderna (MRNA) stake by 28% in Q2 2026, selling an estimated $442K and leaving 21,940 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1725.

Thrivent Financial for Lutherans first reported a position in MRNA in Q4 2020 and has held it in 23 quarters since. The position peaked at $17.3M in Q3 2021. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Thrivent Financial for Lutherans held 21,940 shares of Moderna worth $1.54M as of Q2 2026.
  • Thrivent Financial for Lutherans sold 8,537 Moderna shares in Q2 2026, an estimated $442K.
  • Moderna made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #1725 holding.
  • Thrivent Financial for Lutherans first reported a position in Moderna in Q4 2020 and has held it in 23 quarters since.
  • Thrivent Financial for Lutherans's Moderna position peaked at $17.3M in Q3 2021.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.